Yariv Gerber1, Uri Goldbourt, Micha S Feinberg, Shlomo Segev, Dror Harats. 1. Division of Epidemiology and Preventive Medicine, Sackler Medical Faculty, Tel Aviv University, and Institute of Lipid & Artherosclerosis Research, Sheba Medical Center, Tel-Hashomer, Israel. yarivg@post.tau.ac.il
Abstract
BACKGROUND: Evidence linking cardiovascular risk factors to aortic valve sclerosis (AVS) has led to the assumption that the latter is an atherosclerosis-like process. However, triglyceride (TG)-rich lipoproteins, an important risk factor for atherosclerosis, have been rarely investigated in connection with AVS. METHODS: A cross-sectional study of 246 healthy individuals (mean age 59+/-6 years, 77% men) was conducted. Subjects underwent an echocardiographic assessment and extensive blood lipid measurements, including evaluation of TG-related indices, such as serum apolipoprotein (apo) C(II) and C(III) levels, apo C(III) levels in VLDL+LDL particles, and apo C(III) ratio (C(III) level in HDL/C(III) level in VLDL+LDL). RESULTS: Twenty-three patients (9.3%) were diagnosed as having AVS. On average, these patients were 5 years older and had higher levels of serum cholesterol, LDL-C and LP(a), compared with non-AVS subjects. In addition, the AVS patients exhibited higher concentrations of serum apo C(II), serum apo C(III) and apo C(III) in VLDL+LDL, and a lower apo C(III) ratio. Adjusting for age and gender, a 1 S.D. increment in apo C(III) in VLDL+LDL was associated with odds ratio (OR) of 1.76 (95% CI: 1.17-2.65) for AVS. Further adjustment for atherosclerotic risk factors did not alter the association appreciably (OR=1.65, 95% CI: 1.06-2.58). CONCLUSION: TG-rich lipoproteins may be involved in the early development of AVS. Confirmation in prospective studies is required.
BACKGROUND: Evidence linking cardiovascular risk factors to aortic valve sclerosis (AVS) has led to the assumption that the latter is an atherosclerosis-like process. However, triglyceride (TG)-rich lipoproteins, an important risk factor for atherosclerosis, have been rarely investigated in connection with AVS. METHODS: A cross-sectional study of 246 healthy individuals (mean age 59+/-6 years, 77% men) was conducted. Subjects underwent an echocardiographic assessment and extensive blood lipid measurements, including evaluation of TG-related indices, such as serum apolipoprotein (apo) C(II) and C(III) levels, apo C(III) levels in VLDL+LDL particles, and apo C(III) ratio (C(III) level in HDL/C(III) level in VLDL+LDL). RESULTS: Twenty-three patients (9.3%) were diagnosed as having AVS. On average, these patients were 5 years older and had higher levels of serum cholesterol, LDL-C and LP(a), compared with non-AVS subjects. In addition, the AVS patients exhibited higher concentrations of serum apo C(II), serum apo C(III) and apo C(III) in VLDL+LDL, and a lower apo C(III) ratio. Adjusting for age and gender, a 1 S.D. increment in apo C(III) in VLDL+LDL was associated with odds ratio (OR) of 1.76 (95% CI: 1.17-2.65) for AVS. Further adjustment for atherosclerotic risk factors did not alter the association appreciably (OR=1.65, 95% CI: 1.06-2.58). CONCLUSION:TG-rich lipoproteins may be involved in the early development of AVS. Confirmation in prospective studies is required.
Authors: Aeron Small; Daniel Kiss; Jay Giri; Saif Anwaruddin; Hasan Siddiqi; Marie Guerraty; Julio A Chirinos; Giovanni Ferrari; Daniel J Rader Journal: Arterioscler Thromb Vasc Biol Date: 2017-02-02 Impact factor: 8.311
Authors: Laura Mourino-Alvarez; Tatiana Martin-Rojas; Cecilia Corros-Vicente; Nerea Corbacho-Alonso; Luis R Padial; Jorge Solis; María G Barderas Journal: J Clin Med Date: 2020-07-28 Impact factor: 4.241